Last reviewed · How we verify
Divalproex Sodium Extended-Release Tablets — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Divalproex Sodium Extended-Release Tablets (Divalproex Sodium Extended-Release Tablets) — Virginia Commonwealth University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Divalproex Sodium Extended-Release Tablets TARGET | Divalproex Sodium Extended-Release Tablets | Virginia Commonwealth University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Divalproex Sodium Extended-Release Tablets CI watch — RSS
- Divalproex Sodium Extended-Release Tablets CI watch — Atom
- Divalproex Sodium Extended-Release Tablets CI watch — JSON
- Divalproex Sodium Extended-Release Tablets alone — RSS
Cite this brief
Drug Landscape (2026). Divalproex Sodium Extended-Release Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/divalproex-sodium-extended-release-tablets. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab